Mangoceuticals, Inc. announced a registered direct offering and private placements totaling approximately $2.5 million.
The transactions include the sale of Common Stock and pre-funded warrants to institutional investors.
Proceeds will be used for general corporate purposes and working capital.
Transaction Details
Total gross proceeds expected to be approximately $2.5 million from the offerings priced at the market under Nasdaq rules.
Offering Terms
Offering price per Common Unit is $1.295 with immediate exercisable Pre-Funded Warrants.
Closing Date
Expected to close on or about December 19, 2025, subject to customary closing conditions.
- Mangoceuticals will utilize the net proceeds from the offerings along with existing cash for general corporate purposes and working capital.
- Aegis Capital Corp. is the exclusive placement agent, and Lucosky Brookman LLP and Kaufman & Canoles, P.C. are acting as legal counsels.
The Company's strategic move to raise funds through registered direct offering and private placements aligns with its goal of enhancing product development and market expansion.